Workflow
贝瑞基因(000710) - 2015年4月2日投资者关系活动记录表

Group 1: Restructuring Overview - The restructuring is led by the actual controller, with the project being selected after thorough comparison [2] - The actual controller has a dedicated team for related projects [2] - The restructuring aims to develop a dual-main business model, contingent on the future development of both business segments [3] Group 2: Old Ken Medical's Operations - Old Ken Medical withdrew its IPO application in May 2013 due to market changes and strategic needs [3] - The company is collaborating with the UK New Helix Group to establish a nationwide medical disinfection service outsourcing system [3] - The business performance of Old Ken Medical in January and February of this year has been reported as good [4] Group 3: Management and Financing Post-Reorganization - Post-reorganization, Liu Xia is proposed to be nominated as a candidate for the board of directors and to serve as the deputy general manager of Tianxing Instrument [4] - Daily operations of Old Ken Medical will primarily be managed by its own team, with Tianxing Instrument appointing directors and financial leaders [4] - Financing will mainly support Old Ken Medical, while Tianxing Instrument's significant expenditures will be related to relocation and new factory construction [4] Group 4: Risks and Future Plans - The reorganization faces risks such as regulatory approval, integration challenges, and inherent risks of Old Ken Medical [4][5] - The timeline for completing the reorganization is uncertain and depends on the China Securities Regulatory Commission's review [4][5]